AGF Management Ltd. Invests $590,000 in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

AGF Management Ltd. bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,585 shares of the medical equipment provider's stock, valued at approximately $590,000.

Other large investors have also modified their holdings of the company. Wealthfront Advisers LLC raised its position in Zimmer Biomet by 927.5% in the 4th quarter. Wealthfront Advisers LLC now owns 33,105 shares of the medical equipment provider's stock valued at $3,497,000 after purchasing an additional 29,883 shares during the last quarter. Independent Advisor Alliance purchased a new position in Zimmer Biomet during the 4th quarter worth $2,027,000. Daiwa Securities Group Inc. raised its position in Zimmer Biomet by 6.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 26,630 shares of the medical equipment provider's stock worth $2,813,000 after buying an additional 1,497 shares during the last quarter. FWG Holdings LLC raised its position in Zimmer Biomet by 3.5% during the 4th quarter. FWG Holdings LLC now owns 3,715 shares of the medical equipment provider's stock worth $402,000 after buying an additional 124 shares during the last quarter. Finally, OFI Invest Asset Management purchased a new position in Zimmer Biomet during the 4th quarter worth $40,000. Institutional investors and hedge funds own 88.89% of the company's stock.

Insider Activity at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.95% of the stock is currently owned by insiders.

Remove Ads

Zimmer Biomet Trading Up 0.0 %

Shares of ZBH stock traded up $0.03 during trading hours on Wednesday, hitting $112.91. 1,916,519 shares of the company were exchanged, compared to its average volume of 1,487,494. The firm has a market cap of $22.48 billion, a PE ratio of 25.37, a PEG ratio of 1.95 and a beta of 1.04. Zimmer Biomet Holdings, Inc. has a 1 year low of $97.69 and a 1 year high of $133.90. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The firm has a fifty day moving average of $106.18 and a 200 day moving average of $106.88.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter last year, the company posted $2.20 EPS. Analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.24 dividend. The ex-dividend date is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.85%. Zimmer Biomet's payout ratio is 21.57%.

Wall Street Analyst Weigh In

A number of equities analysts have commented on ZBH shares. Needham & Company LLC restated a "hold" rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Barclays cut their price target on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a report on Monday, February 10th. JMP Securities reiterated a "market outperform" rating and issued a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 7th. Royal Bank of Canada lowered their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, February 7th. Finally, Truist Financial reissued a "hold" rating and issued a $113.00 price objective (down from $118.00) on shares of Zimmer Biomet in a research note on Monday, February 10th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.